Families in the Duchenne muscular dystrophy (DMD) community living in England received encouraging news this week. The National Institute for Health and Care Excellence (NICE) has issued its final draft guidance recommending that the treatment Duvyzat (givinostat) should be funded for people aged 6 and over who are still able to walk or stand, with or without help, when they start treatment.
The recommendation applies only to the group of patients studied in clinical trials, rather than everyone the medicine is licensed for. It is the third treatment for DMD that NICE has recommended for NHS use. Around 530 people in England are expected to be eligible. Funding will be made available immediately through the Innovative Medicines Fund, which allows patients early access to promising new treatments while further evidence is gathered.
NICE described Duvyzat as a promising treatment while acknowledging there are still unanswered questions surrounding its long-term benefits. Even so, decision-makers concluded that the potential advantages for people living with DMD were meaningful enough to justify public funding support. The recommendation reflects a growing recognition among healthcare leaders that rare disease communities urgently need access to innovative therapies, even as additional evidence continues to emerge over time.
Unlike some DMD therapies that are designed to work for only specific genetic mutations, Duvyzat has the potential to benefit a much broader group of people living with DMD. That wider eligibility has made the treatment especially significant for families with limited therapeutic options.
DMD is a progressive muscle-wasting condition that gradually affects mobility, independence, heart function, and respiratory health. For many families, slowing disease progression can mean more years of walking, more independence, and more time participating in everyday life experiences.
Clinical trial findings suggest that children receiving this treatment alongside standard care (such as steroids) have a higher chance of walking (on average) up to five years longer compared to those receiving standard treatment alone. Researchers continue to study the medication to better understand its long-term impact and overall effectiveness.
NICE is a health technology assessment (HTA) body that evaluates the clinical and cost-effectiveness of drugs, devices and diagnostics, similar to Canada’s Drug Agency.
The Power of Patient Voices:
One of the most influential parts of the review process came directly from families and patient advocates.
Members of the DMD community in England shared deeply personal experiences about the realities of living with DMD. According to officials involved in the review, these testimonies helped reinforce the importance of expanding access to new treatment options and highlighted the urgent need for continued investment in rare disease therapies.
While Duvyzat t is not a cure for Duchenne muscular dystrophy, the recommendation marks another important step forward in the evolving landscape of DMD treatment. For many families, it also represents something equally important: renewed hope for more time, more mobility, and more possibilities for the future.
Why This Could Matter for Canada:
Duvyzat is not yet approved in Canada, but it is already approved in the United States, European Union, and the United Kingdom. In Canada, Health Canada decides whether a drug is safe and effective and can be sold in the country.
Although Health Canada does not directly approve drugs based on funding recommendations from NICE, NICE’s funding recommendation for Duvyzat may help inform later discussions in Canada about whether public drug plans may cover the treatment, including reviews by Canada’s Drug Agency and other payers.
Overall, NICE’s recommendation is a supportive signal. It does not mean Duvyzat will automatically be approved or publicly funded in Canada, but it does add to the evidence that Duvyzat may be a meaningful treatment option for some people living with DMD. The NICE recommendation may also help Canadian patient advocacy efforts by showing that another publicly funded health system has recognized the potential value of the treatment.
Looking ahead, patient advocacy will be especially important for Duvyzat in Canada because rare disease treatments often have limited clinical evidence due to the small number of patients available for clinical trials. Advocacy groups play a critical role in helping decision-makers understand that smaller studies do not necessarily mean a treatment is ineffective, particularly in serious and progressive conditions like DMD where time is muscle.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: